Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries, a generic pharmaceutical company, has announced that the FDA has granted final approval for the company's abbreviated new drug application to market its generic version of GlaxoSmithKline's Imitrex tablets, 25mg, 50mg and 100mg for treatment of acute migraine attacks. Shipment of this product has commenced.
Subscribe to our email newsletter
As one of the first companies to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has obtained a 180-day period of marketing exclusivity.